{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$3.54 vs. cons $3.48",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$6.62B vs. cons $6.57B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic sales growth (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~9.5% vs. cons ~8.9%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 Adjusted EPS guide",
      "prediction": "BETTER",
      "answer": "guide ~$15.05-15.30 vs. cons $14.90-15.10 (FY26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 organic sales growth guide",
      "prediction": "BETTER",
      "answer": "guide ~9-10% vs. prior/cons 8-9.5% (FY26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 adj. operating margin expansion",
      "prediction": "UNCHANGED",
      "answer": "guide ~+50bps vs. cons ~+50bps (FY26)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -1.0,
  "day5_path": "FADE",
  "day5_rationale": "SYK is a reliable beat-and-raise, so a clean recovery-quarter beat with a modest FY raise likely lifts the stock day 1. But the ~13% pre-print rally ($309 on 7/22 to $350 on 7/29) already prices in the recovery, and a chunk of the Q2 upside is one-time rev-rec catch-up of Q1 cyber-deferred sales rather than incremental forward demand. With limited true out-period estimate revision and a very high bar, profit-taking fades the initial pop over the following week toward a small net-negative residual.",
  "day5_confidence": "MEDIUM"
}